NF-kB and IKK as Key Mediators of Inflammation and Oncogenic Progression - Transcription Factors NF-kappaB - page 174

[97] Catley, M.C. et al., Validation of IKKβ as a therapeutic target in airway inflammation

disease by adenoviral delivery of dominant negative IKKβ to pulmonary epithelial
cells, Br. J. Pharmacol., 145, 114, 2005.

[98] Kopp, E. and Ghosh, S., Inhibition of NF-κB by sodium salicylate and aspirin,

Science, 270, 2017, 1994.

[99] Yin, M.J., Yamamoto, Y., and Gaynor, R.B., The anti-inflammatory agents aspirin and

salicylate inhibit the activity of IKKβ, Nature, 396, 15, 1998.

[100] Takada, Y. et al., Nonsteroidal anti-inflammatory agents differ in their ability to

suppress NF-κB activation, inhibition of Cox-2 and cyclin D1, and abrogation of
tumor cell proliferation, Oncogene, 23, 9247, 2004.

[101] Farmer, P. and Pugin, J., β2-adrenergic agonists effect their anti-inflammatory effects

on monocytic cells through the IκB/NF-κB pathway, Am. J. Physiol. Lung Cell. Mol.
Physiol ., 279, L615, 2000.

[102] Lawrence, T. et al., IKKα limits macrophage NF-κB activation and contributes to

the resolution of inflammation, Nature, 434, 1238, 2005.

[103] Baldwin, A.S., Control of oncogenesis and cancer therapy resistance by the transcrip-

tion factor NF-κB, J. Clin. Inv ., 107, 241, 2001.

[104] Karin, M. et al., NF-κB in cancer: From innocent bystander to major culprit, Nat.

Rev. Cancer, 2, 301, 2002.

[105] Pianetti, S. et al., Her-2/neu overexpression induces NF-κB via a PI3-kinase/Akt

pathway involving calpain-mediated degradation of IκBα that can be inhibited by
the tumor suppressor PTEN, Oncogene, 20, 1287, 2001.

[106] Hanson, J.L. et al., NF-κB subunits RelA/p65 and c-Rel potentiate but are not required

for Ras-induced cellular transformation, Cancer Res ., 64, 7248, 2004.

[107] Reuther, J.Y. et al., A requirement for NF-κB in Bcr-Abl-mediated transformation,

Genes Dev., 12, 968, 1998.

[108] Zhou, H., Du, M., and Dixit, V.M., Constitutive NF-κB activation by the

t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin
ligase activity, Cancer Cell, 7, 425, 2005.

[109] Rocha, S. et al., Regulation of NF-κB and p53 through activation of ATR and Chk1

by the ARF tumor suppressor, Embo J ., 24, 1157, 2005.

[110] Kim, J.H. et al., Transcriptional regulation of a metastasis suppressor gene by Tip60

and beta-catenin complexes, Nature, 434, 921, 2005.

[111] Biswas, D.K., EGF-induced NF-κB activation: A major pathway of cell-cycle pro-

gression in estrogen receptor negative breast cancer cells, Proc. Nat. Acad. Sci., USA ,
97, 8542, 2000.

[112] Sitcheran, R. et al., Positive and negative regulation of EAAT2 by NF-κB: A role for

N-myc in TNF-controlled gene repression, Embo J ., 24, 510, 2005.

[113] Dajee, M. et al., NF-kB blockade and oncogenic Ras trigger invasive human epidermal

neoplasia, Nature, 421, 639, 2003.

[114] Zhang, J.Y. et al., NF-κB RelA opposes epidermal proliferation driven by TNFR1

and JNK, Genes Dev ., 18, 17, 2004.

[115] Ryan, K.M. et al., Role of NF-κB in p53-mediated programmed cell death, Nature,

404, 892, 2000.

[116] Deng, J. et al., β-catenin interacts with and inhibits NF-κB in human colon and breast

cancer, Cancer Cell, 2, 323, 2002.

[117] Perkins, N.D., NF-κB: Tumor promoter or suppressor, Trends Cell Biol ., 14, 64, 2004.

[118] Lam, L.T. et al., Small molecule inhibitors of IKKs are selectively toxic for subgroups

of diffuse large B-cell lymphoma defined by gene expression profiling, Clin. Cancer
Res ., 11, 28, 2005.